share_log

BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21

BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21

BMO資本開始對igm biosciences進行覆蓋,評級爲跑贏大盤,宣佈價格目標爲21美元。
Benzinga ·  2024/12/06 04:52  · 評級/大行評級

BMO Capital analyst Etzer Darout initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces Price Target of $21.

BMO Capital 分析師Etzer Darout對igm biosciences(納斯達克:IGMS)啓動了覆蓋,給予了跑贏大盤的評級,並宣佈了21美元的價格目標。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論